阿替利珠单克隆抗体联合贝伐珠单克隆抗体一线治疗晚期巨块型肝细胞癌的临床疗效

Clinical efficacy of atezolizumab plus bevacizumab in the first-line treatment of advanced huge hepatocellular carcinoma

我国是肝癌高发国家,主要为肝细胞癌,病死率较高,严重威胁人民生命健康。既往针对晚期肝癌的治疗手段缺乏,总体预后差。近年来,免疫和靶向药物已被推荐作为晚期肝细胞癌治疗的有效手段。笔者报道1例晚期巨块型肝细胞癌患者,行阿替利珠单克隆抗体联合贝伐珠单克隆抗体治疗后6个月的初步临床效果。其研究结果显示:患者治疗3个月后肝内肿瘤病灶缩小32.4%,治疗6个月后缩小47.5%,甲胎蛋白和肿瘤异常蛋白持续降低,肿瘤达到部分缓解,无不良反应发生,获得近期良好疗效。

The incidence and mortality of hepatocellular carcinoma(HCC)is very high in China,which seriously threatens human life and health.There were limited treatment options for advanced HCC in the past,and the overall survival of HCC patients was poor.In recent years,immuno-therapy and targeted therapy have been recommended as effective means for the treatment of advan-ced HCC.The authors report a case of advanced huge HCC which has achieved a maintained partial response for 6 months after the treatment of atezolizumab combined with bevacizumab.The tumor shrunk by 32.4%and 47.5%after 3 and 6 months of treatment.Besides,the alpha-fetoprotein and abnormal tumor protein value of the patient continued to decrease without any adverse reactions.The treatment is evaluated as partial response and patients has a good short-term effect.